S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Middle-Class Insulin Users Face Staggering Monthly Costs

Nearly 40 percent of insulin-dependent patients currently pay over $150 each month for their medication, according to new data from the American Diabetes Association. The findings highlight a widening gap in affordability, particularly among middle-income earners who remain excluded from existing state-level and federal price protections.

Middle-Class Insulin Users Face Staggering Monthly Costs
Photo: Bio & News

The financial burden is most acute for households earning between $75,000 and $99,000 annually, where 55 percent of insulin users report monthly expenditures exceeding $150. Even among those making $50,000 to $75,000, 44 percent face similar costs. These expenses are driving broader lifestyle sacrifices, with one-third of survey respondents reporting they have reduced grocery budgets to cover healthcare, while nearly a quarter have delayed or skipped medical appointments entirely.

While Medicare and 29 states have capped cost-sharing, those enrolled in private or employer-sponsored health plans often pay upwards of $400 monthly. A bipartisan push led by Senators Jeanne Shaheen, Susan Collins, Raphael Warnock, and John Kennedy seeks to address this via the INSULIN Act of 2026, which would standardize the $35 monthly cap for the private market. ADA Chief Advocacy Officer Lisa Murdock warned that half of insulin-dependent patients are currently rationing their supply, underscoring the urgency for legislative intervention.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!